This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Safeway Campaign Raises $10.3 Million For Prostate Cancer Research

PLEASANTON, Calif., Sept. 6, 2013 /PRNewswire/ -- Safeway Inc. (NYSE: SWY), one of the largest corporate supporters of cancer research and outreach, today announced that its stores raised $10.3 million during the company's annual Prostate Cancer Awareness campaign.


For the 13 th year in a row, Safeway's entire chain of more than 1,600 stores dedicated an entire month to raising money and increasing awareness for the fight against prostate cancer, which currently affects more than two million American men and remains the second-leading cause of cancer death for men in the United States. One in six men will be diagnosed with prostate cancer in their lifetime. To date, Safeway's customers have donated nearly $86.8 million to the cause.

"We'd like to express our gratitude to our customers who have, year after year, shown commitment to this important cause by contributing and helping to save lives, one dollar at a time," said Larree Renda, Safeway Executive Vice President and Chair of the Safeway Foundation.

To identify the most promising and groundbreaking prostate cancer research projects for funding, Safeway and The Safeway Foundation partner with a range of cancer research organizations such as  the Prostate Cancer Foundation, Stand Up to Cancer, and the University of California at San Francisco. The donations have funded more than 1,600 research projects, yielding several leading-edge, life-saving treatments.

Over the past three years alone, six new prostate cancer drugs were approved by the Food and Drug Administration and dozens of new drugs are currently in trials due to Safeway's support. Safeway's support has also led to a treatment that may decrease cancer deaths by 20 percent per year by deploying new combinations of surgery and medications early in the course of the disease. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs